1-2 of 2
François Lemonnier
Close
Sort by
Journal Articles

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Clinical Trials & Observations
François Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, Anne-Ségolène Cottereau, Emmanuel Bachy, Guillaume Cartron, Virginie Fataccioli, Laura Pelletier, Cyrielle Robe, Audrey Letourneau, Edoardo Missiaglia, Slim Fourati, Marie-Pierre Moles-Moreau, Alain Delmer, Reda Bouabdallah, Laurent Voillat, Stéphanie Becker, Céline Bossard, Marie Parrens, Olivier Casasnovas, Victoria Cacheux, Caroline Régny, Vincent Camus, Marie-Hélène Delfau-Larue, Michel Meignan, Laurence de Leval, Philippe Gaulard, Corinne Haioun
Journal: Blood Advances
Blood Adv (2021) 5 (2): 539–548.
https://doi.org/10.1182/bloodadvances.2020003081
Published: 2021
Includes: Supplemental data
Journal Articles

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Clinical Trials & Observations
Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, Rene-Olivier Casasnovas, François Lemonnier, Gian Matteo Pica, Roch Houot, Loic Ysebaert, Hervé Tilly, Jean-Claude Eisenmann, Steven Le Gouill, Vincent Ribrag, Pascal Godmer, Sylvie Glaisner, Guillaume Cartron, Luc Xerri, Gilles André Salles, Thierry Fest, Franck Morschhauser
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3217–3223.
https://doi.org/10.1182/bloodadvances.2020001955
Published: 2020
Includes: Supplemental data